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Abstract: Little data exists concerning the efficacy of the antiretroviral therapy in the Federal District in Brazil, therefore in order to 
improve HIV/AIDS patients’ therapy and to pinpoint hot spots in the treatment, this research work was conducted. Of 139 HIV/AIDS 
patients submitted to the highly active antiretroviral therapy, 12.2% failed virologically. The significant associated factors related to 
unresponsiveness to the lentiviral treatment were: patients’ place of origin (OR = 3.28; IC95% = 1.0–9.73; P = 0.032) and Myco-
bacterium tuberculosis infection (RR = 2.90; IC95% = 1.19–7.02; P = 0.019). In the logistic regression analysis, the remaining vari-
ables in the model were: patients’ birthplace (OR = 3.28; IC95% = 1.10–9.73; P = 0.032) and tuberculosis comorbidity (OR = 3.82; 
IC95% = 1.19–12.22; P = 0.024). The patients enrolled in this survey had an 88.0% therapeutic success rate for the maximum period 
of one year of treatment, predicting that T CD4+ low values and elevated viral loads at pretreatment should be particularly considered 
in tuberculosis coinfection, besides the availability of new antiretroviral drugs displaying optimal activity both in viral suppression and 
immunological reconstitution.
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Introduction
Plasmatic viral load strongly predicts T CD4+ cell 
count decline, AIDS progression and death. Anyway, 
disease prognosis in HIV infected subjects is more 
rigorously defined by the combination of plasmatic 
viral load quantification and T CD4+ cell count.1 It 
is internationally noted that the main predictive fac-
tors for failure of antiretroviral therapy are T CD4+ 
cells low count and elevated viral load before com-
mencing treatment.2 The efficacy of the Highly Active 
Antiretroviral Therapy (HAART) and the pattern of 
therapy  management  could  be  evaluated  based  on 
plasmatic RNA viral load assessement. In HIV/AIDS 
treatment the response is considered successful when 
the HIV RNA levels remain undetectable by certi-
fied commercial assays, notwithstanding in a variable 
proportion of HAART submitted patients, the viral 
replication and evolution goes on which could even-
tually contribute to the development of antiretroviral 
drug resistance and therapeutic failure.3
Unsuccessful  antiretroviral  therapy  could  occur 
due to virologic and immunologic failure and clinical 
manifestations that can appear during the course of 
HIV infection. The identification of therapeutic failure 
is based on patient follow-up during treatment, taking 
into account the initial level of T CD4+, plasmatic HIV 
RNA load and the patient clinical evolution. Also, 
many factors could be related to therapeutic failure 
such as low treatment adhesion, insufficient drug dos-
age, mal-absorption, HIV antiretroviral resistance and 
drug interactions that could reduce the efficacy and 
HIV resistance to antiretroviral   medications. Patients 
that failed to respond to antiretroviral therapy con-
firmed by the genotype resistant assay will be guided 
to choose new drugs. This choice is based on the 
knowledge of previous treatments and yet the reason 
to remove a drug from the antiretroviral regimen is 
mainly justified by the in vitro antiretroviral resistance 
profile. The antiretroviral therapeutic suspension as 
an alternative therapy is based on the reemergence of 
the initial virus population before treatment initiation, 
which would be susceptible to the antiretroviral drugs 
earlier prescribed, so this proposal is presently under 
  evaluation. The    essential  objective  of  treatment  in 
patients presenting therapeutic failure is to maintain 
T CD4+ acceptable cell population density, whilst new 
therapeutic options are awaited, contrary to the prior-
ity aim to reach and keep up an undetectable viral 
load.4 According to Moore et al,5 virological failure 
is characterized by viral load higher than 400 cop-
ies/mL after 48 weeks of initial treatment or among 
subjects that had complete viral suppression, but later 
on the viral load will recrudesce. The viral failure 
precedes the immunologic failure which is defined 
by a decline of more than 25.0% in the subsequent 
count of T CD4+ lymphocytes or regresion to the ini-
tial T CD4+ cell count before treatment. These condi-
tions are mainly suggestive of immunologic failure 
but laboratory analysis confirmation is mandatory.6 
Cozzi-Lepri et al7 concluded that patients remaining 
in HAART failure presented viral load slowly pro-
gressing during the next 12 months, differently to T 
CD4+ cell count which remained stable.
The impact of HAART on T CD4+ cell count and 
viral load of HIV infected patients has been dem-
onstrated  to  improve  the  patient’s  immunological 
status and it also diminished the viral load, interrupt-
ing the AIDS progression.8 However there are cru-
cial limitations of HAART regimen, as it does not 
eradicate viral infection despite long and permanent 
antiretroviral  therapy.  Consequently,  a  significant 
number of these patients on HAART therapy develop 
viral  resistance  to  the  drugs  besides  diverse  side 
effects including metabolic disorders. Therefore new 
approaches are necessary to control and/or eradicate 
HIV infection.9,10
This  research  work  aimed  to  analyze  T  CD4+ 
cell density and viral load response in HIV infected 
patients  undergoing  different  therapeutic  regimens 
which  failed  virologically,  and  also  the  associated 
factors to it during 2002–2008 in Brasilia, Federal 
District, Brazil.
Material and Methods
Patients
A cohort study was conducted in the Health Cen-
ter Number 01 attached to the Secretary of Health, 
  Federal  District  (SES/DF)  (Centro  de  Saúde 
Número 01,   Secretaria de Saúde do Distrito   Federal) 
which  included  139  HIV-1  infected  patients.  The 
patients  had  clinical  and  laboratory  diagnosis  as 
defined by the 1993 AIDS clinical course criteria and 
by the US Center for Disease Control (CDC)11 and 
also by the recommendations of the Brazilian Con-
sensus of   Antiretroviral Therapy in Infected Adults 
and   Adolescents by the Ministry of Health, Secretary of Antiretroviral treatment in the federal district, Brazil, Federal District 
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Health Surveillance, Brazilian National Program of 
Sexually Transmitted Diseases and AIDS.12 Patients 
selected for the study were identified in the records of 
Logistic System of the Ministry of Health, SICLOM13 
utilized by the Hospital Dia, SES/DF.
The plasmatic HIV RNA load was quantified by the 
BDNA system 340 presenting   sensitivity of less than 
50 copies/mL. The T CD4+ helper   lymphocytes’ count 
was carried out by automatized flow   cytometry uti-
lizing the FacScalibur Count® System. The   sampling 
  utilized for patient selection was by convenience whose 
inclusion criteria were: (a) age higher than 18 years 
old and of both sexes; (b) HIV   infection   diagnosis 
defined  by  the  Brazillian  Ministry  of  Health  stan-
dardized patterns; (c) detectable viral load   previous 
to HAART beginning .400 copies/mL; (d) T CD4+ 
cell count ,500 cells/mm3 before HAART regimen 
  initiation;  (e)  present  laboratory  analysis  for  viral 
load and T CD4+ count between 6 and 12 months in 
order to compare the former ones with those of base-
line; (f) patients have had clinical and immunological 
  follow up during 3 months intervals.
If undetectable viral load of 50 copies/mL was not 
sustained during 24 weeks of treatment or higher than 
400 copies/mL after 48 weeks treatment, it was consid-
ered virological failure to the initial antiretroviral thera-
peutic regimen.5 Immunological failure was considered 
by the declining of T CD4+ cell counting $ 25.0% of the 
absolute values6 or by returning to the T CD4+ cell count 
initial values before antiretroviral therapy initiation.
The viral load previous to HAART regimen initia-
tion and T CD4+ cell count were evaluated as possible 
predictors of viral failure leading us to establish the 
cut off values to viral load . 100.000 copies/mL or 
#100.000 copies/mL as also T CD4+ . 200 cells/mm3 
or #200 cells/mm3.
The antiretroviral therapy regimen were: (a) double 
with two nucleoside reverse transcriptase inhibitor 
and non nucleoside reverse transcriptase inhibitor; 
(b) triple with two nucleoside reverse transcriptase 
inhibitor  and  one  protease  inhibitor  and  (c)  three 
nucleoside  reverse  transcriptase  inhibitor,  accord-
ing to CDC classification and the Brazilian Minis-
try  of  Health  guidelines  as  previously  described. 
In the population here studied, the chosen antiret-
roviral  regimen  was  decided  by  the  physician  in 
charge without interference by the authors of this 
research work.
The criteria for the diagnosis of Hepatitis B and C 
virus infection followed the guidelines established by 
the Manual of Viral Hepatitis Consultancy, Secretary of 
Health Surveillance, Department of   Epidemiological 
Surveillance, Brasília, Ministry of Health14 and also 
for the tuberculosis diagnosis, the Technical   Manual 
for Tuberculosis Control, Notebook of Basic   Attention, 
Secretary  of  Health  Politics,  Department  of  Basic 
Attention, Brasília. Ministry of Health.15
The exclusion criteria for this research were: (a) be 
pregnant or minor under 18 years old; (b) be prescribed 
with medications which could metabolically interact 
with  antiretroviral  drugs,  including    phytotherapics; 
(c)  have  had  last  clinical  appointment  in  a  period 
longer than 6 months which was considered lost to 
follow-up.
The  analysis  of  baseline  characteristics  (initial 
data previous to initiation of treatment referring to T 
CD4+ cell count and viral load) included frequency 
tables of categorical variables and their descriptive 
statistics  (median,  arithmetic  mean  and  standard 
deviation) as also as continuous variables. In order to 
measure the dependent association between two cat-
egorial variables it was utilized the Chi-square test 
(x2) or when necessary the exact Fisher test. To com-
pare before and after results the MacNemar test was 
applied. For the analysis of logistic regression and 
to predict the event of virological failure16   (depedent 
variable), the WALD method was applied. The asso-
ciation  measurement  calculated  from  the  logistic 
model is the adjusted odds ratio (OR). The statis-
tical analysis was carried out utilizing SPSS 17.0. 
The  statistical  association  was  considered  when 
P , 0.05.
The patients’ data were confidential and consent-
ment to utilize information were obtained at the Health 
Center Number 01 direction according to the Federal 
District Secretary (SES/DF) of Health   agreement. The 
research work protocol was approved by the Federal 
District Secretary of Health Researh Ethics Commit-
tee, Foundation of Teaching and Research in Health 
Sciences (FEPECS).
Results and Discussion
Initially,  165  patients  were  eligible  to  participate 
in the study for starting the treatment in the period 
2002–2008.  However,  only  139  patients  met  the 
inclusion criteria. Among  them (Table 1A  and  B), Bello et al
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males  predominated  (74.1%).  Ages  ranged  from 
20–65 years old (mean = 39.7 years, median = 40.0). 
There was a slight predominance of patients in the 
range of 41–65 years old (51.1%) compared to younger 
patients. As for race/ethnical background, there was 
a predominance of mestizos (54.6%). Regarding to 
the marital status, there was a predominance of sin-
gle people (48.2%). High school education (25.9%) 
predominated over other categories. People living in 
Taguatinga (13.7%), a satellite city located in the sur-
rounding areas of Brasília, represented the majority of 
the patients enrolled in this study. The place of birth 
showed that patients predominated from the Midwest 
(40.3%) and the Northeast of Brazil (34.5%). Hetro-
sexual relationships predominated (51.8%), followed 
by the homosexual relationships (23.7%).
The  initial  viral  load  ranged  between  1.643 
copies/mL to 500.000 copies/mL (mean = 180.721 
copies/mL; arithmetic mean = 126.417 copies/mL) 
  presenting  more  than  half  of  the  patients  (55.4%) 
cell density higher than 100.000 copies/mL (Table 2). 
After antiretroviral therapy, the initial profile changed 
substantially more than 70% of the patients had viral 
load lower than 50 copies/mL. In reference to the ini-
tial T CD4+ cell count, 68.3% of the patients were 
in the range of 0–200 cells/mm3. After treatment a 
relevant change was observed in the patients pro-
file concerning T CD4+ cell counts, remaining less 
than 37% of the cases in this stage. In the following 
cell density interval, there was an expressive incre-
ment in the number of cases, representing more than 
43.0% of the patients (Table 2). Initially the most uti-
lized antiretroviral regimen included two drugs, the 
nucleoside  reverse  transcriptase  inhibitor  and  non 
nucleoside reverse transcriptase inhibitor in 71.2% 
of the cases and the remaining 28.1% included two 
nucleoside  reverse  transcriptase  inhibitor  and  one 
protease inhibitor. During the course of the treat-
ment,  the  presented  regimen  distribution  slightly 
changed to 66.9% to the first drug combination and 
Table 1B. Distribution of socioeconomic and demographic 
profile  of  patients  attended  in  the  Health  Center  No.  1 
  (hospita Dia) during 2002–2008.
Variable category n %
residence Pilot Plan 29 20.9
guara 16 11.5
ceilandia 17 12.2
Taguatinga 19 13.7
Bandeirante 9 6.5
gama 14 10.0
Sobradinho 3 2.2
Planaltina 4 2.9
San Sebastian 7 5.0
Paranoa 2 1.4
Around Brasília 19 13.7
Birthplace north 4 2.9
northeast 48 34.5
South 4 2.9
Southeast 25 18.0
Midwest 56 40.3
African continent 2 1.4
exposure category Accident at work 1 0.7
Bisexual 23 16.7
heterosexual 72 51.8
homosexual 33 23.7
Blood transfusion 1 0.7
UDI 9 6.6
Total 139 100
source: SIcLOM (MS-Brazil).
Abbreviation: UDI, User injecting drug.
Table 1A. Distribution of socioeconomic and demographic 
profiles  of  patients  attended  at  Health  Center  No.  1 
  (hospital Dia) during 2002–2008.
Variable category n %
Sex Male 103 74.1
Female 36 25.9
Age 20–40 68 48.9
41–65 71 51.1
race/ethnical  
background
White 60 43.2
Mestizo 76 54.6
Black 3 2.2
Marital status Single 67 48.2
Married 41 29.5
Stable 18 12.9
Separate 10 7.2
Widow 3 2.2
education Incomplete elementary  
schooling
28 20.1
complete elementary  
schooling
24 17.3
Middle incomplete  
schooling
19 7.2
Middle complete  
schooling
36 25.9
Incomplete higher  
schooling
4 2.9
complete college  
schooling
27 19.4
Illiterate 9 6.5
not informed 1 0.7
Total 139 100.0
source: SIcLOM (MS-Brazil).Antiretroviral treatment in the federal district, Brazil, Federal District 
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32.4% to the second one, there remaining only one 
utilizing three nucleoside reverse transcriptase inhibi-
tor (Table 2).
Virologic  failure  was  12.2%  (Table  3),  or  anti-
retroviral  treatment  success  was  88.8%,  exceeding 
the results obtained by Johnson and Way of 80%.17 
Among  the  socioeconomic  and  demographic  vari-
ables, just the birthplace and the fact that originating 
in the Midwest Region which includes the Federal 
District, was associated with the occurrence of viro-
logic failure in the study. Cole et al18 stated that HIV 
infection is sufficiently widespread, suggesting that it 
is a   multidimensional epidemic, with demographic, 
residential,  social,  biological  and  behavioral  sig-
nificance.   Perhaps this is a natural social structural 
marker as the study was conducted in the Midwest 
region compared to those migrating people from other 
regions  to  the  Federal  District. There  was  a  trend 
toward a higher incidence of virologic failure being 
male, over 40 years old, mestizo, unmarried or sepa-
rate and also heterossexual exposure category. How-
ever, there was not any statistical significance of such 
  associations.  It  was  found  that  only  the    birthplace 
presented    statistical  significance.  Patients  from  the 
Midwestern had 2.7 times greater risk of virologic 
failure than those from other regions of Brazil, espe-
cially because the study was conducted in Brasilia, 
which is part of this region.
In this study, the initial viral load is not statisti-
cally associated and significant to the occurrence of 
virologic failure. However, there is the presence of 
a higher incidence of virologic failure among those 
who had viral load greater than 100.000 copies/mL 
after the introduction of HAART. The virologic tar-
get for patients on HAART is to achieve viral load 
plasma  levels  below  50  copies/mL  when  two  or 
more potent drugs are used. These results highlight 
the importance of compliance with primary success 
and reinforces the need to work on the accession 
of such patients. Some authors19 interpret and agree 
that those with viral load higher than the baseline 
level of 100.000 copies/mL had a slower pace to 
achieve viral suppression. However, a potent and 
well   tolerated prophylactic regimen with HAART 
can improve CD4+ T cell count at the beginning, 
during and after treatment. Kantor et al2 concluded 
Table 2. Viral load and T cD4+ cell counts distribution in 139 patients submitted to antiretroviral therapy in the health center 
no. 1 (hospital Dia) during 2002–2008.
Variable category n %
Initial viral load (treatment-naive) ,50 copies/mL 0 0
50.1–400 copies/mL 0 0
400.1–10,000 copies/mL 5 3.6
10,000.1–100,000 copies/mL 57 41.0
100,0000.1–500,000 copies/mL 77 55.4
Viral load after hAArT ,50 copies/mL 99 71.2
50.1–400 copies/mL 20 14.4
400.1–10,000 copies/mL 10 7.2
10,000.1–100,000 copies/mL 8 5.8
100,000–500,000 copies/mL 2 1.4
Initial T cD4+ cell counts (treatment-naive) 0–200 cells/mm3 96 68.4
200.1–350 cells/mm3 37 26.6
351–500 cells/ 7 5.0
above de 500 cells/mm3 0 0
T cD4+ cell counts after hAArT 0–200 cells/mm3 51 36.7
200.1–350 cells/mm3 60 43.2
351–500 cells/mm3 21 15.1
above de 500 cells/mm3 7 5.0
hAArT 2 ITrn + 1 ITrnn 99 71.2
2 ITrn + 1 IP 39 28.1
3 ITrn 1 0.7
139 100
Abbreviations:  hAArT,  highly  active  antiretroviral  therapy;  nrTI,  nucleoside  reverse  transcriptase  inhibitor;  nnrTI,  non-nucleoside  reverse 
transcriptase inhibitor.Bello et al
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that  plasma  viral  load  strongly  predicts  the  rate 
of CD4+ lymphocyte count decrease, progression 
to AIDS and death. But the prognosis for people 
infected with HIV is more strictly defined by the 
combination of plasma viral load measurement and 
CD4+ lymphocytes’ counts.
Some patients with viral load higher than 100.000 
copies/mL remained in treatment failure after HAART 
regimen  in  contrast  to  T  CD4+  lymphocyte  counts 
decrease at a slower pace, leaving some in virologic 
failure, probably due to the emergence of HIV resistant 
strains. Cozzi-Lepri et al7 advocate that patients who 
remained in HAART regimen failure, the viral load in 
the next twelve months was growing at a relatively slow 
pace, the CD4+ T cell count was stable and the time course 
of viral replication in patients with virological failure 
Table 3. Distribution of variables, viral load, T cD4+ cell counts, HAART and comorbidity in relation to the significance of 
virologic failure in patients treated at the health centre no. 1 (hospital Dia) during 2002–2008.
Variable category VF n cI% RR cI95% P
Sex Male 103 14 13.6 1.63 0.49–5.35 0.407
Female 36 3 8.3
Age 41–65 60 10 16.7 1.88 0.76–4.75 0.164
20–40 79 7 8.9
race Mestizo 79 10 12.7 1.08 0.43–2.68 0.860
White 60 7 11.7
Marital status Single/separate 80 11 13.8 1.35 0.53–3.44 0.524
Married/stable union 59 6 10.2
education nF incomplete/illiterate 38 6 15.8 1.45 0.57–3.64 0.432
Other school levels 101 11 10.9
residence Brasilia suroundings 19 3 15.8 1.35 0.42–4.27 0.610
Pilot plan/satellite city 120 14 11.7
Birthplace Midwest 56 11 19.6 2.71 1.06–6.92 0.028
north, northeast, south, southeast 83 6 7.2
exposury category heterosexual 83 11 13.3 1.23 0.48–3.15 0.654
homosexual 56 6 10.7
Abbreviations: N, patients number; VF, virological  failure; CI, incidence coefficient; RR, relative risk; IC95%,  interval  confidence; P, significance: 
nF, Uninformed.
Table 4. Distribution of association of viral load, T cD4+ cell count, HAART and comorbidities in terms of the significance of 
virologic failure in patients treated at the health centre no. 1 during the years 2002 to 2008.
Variable category n VF Ic% RR Ic95% P
Viral load after hAArT .100.000 77 10 13.0 1.15 0.46–2.84 0.762
#100.000 62 7 11.3
T cD4+ cell after hAArT .200 95 8 10.5 0.66 0.27–1.63 0.368
#200 44 9 15.9
hAArT 2 ITrn + 1 ITrnn 100 12 12.0 0.93 0.35–2.48 0.804
2 ITrnn + 1 IP 39 5 12.8
hcV (hcV-anti) Positive 10 1 10.0 0.80 0.11–3.47 0.823
negative 129 16 12.4
hBV (hBsAg) Positive 31 3 9.7 0.74 0.22–2.43 0.623
negative 108 14 13.9
TB (BAAr) Positive 22 6 27.3 2.90 1.19–7.02 0.019
negative 117 11 10.3
Total 139 17
Abbreviations:  hAArT,  antiretroviral  therapy;  T  cD4+,  lymphocyte  count;  n,  number  of  patients;  VF,  virologic  failure  values;  cI,  incidence  rate; 
RR, relative risk; IC95%, confidence interval; P, significance; HCV, antibody to the hepatitis “C”virus; HBV, antibody against hepatitis “B” virus antigens; 
TB, tuberculosis; BAAr, Alcohol acid resistant bacilli.Antiretroviral treatment in the federal district, Brazil, Federal District 
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had not been fully elucidated. Asjo and Langeland20 
suggest that the lack of complete suppression of viral 
replication allows the continued development of HIV 
variants with different degrees of resistance. It results 
not only in treatment failure, but it also increases the 
risk of HIV primary resistance and dissemination.
Patients with initial CD4+ T cell count # 200 cells/mm3 
had a tendency to virologic failure, however, there 
was not any statistical significance. Tuberculosis coin-
fection was associated with virologic failure demon-
strated with statistical significance, P = 0.019. Patients 
with a previous diagnosis of tuberculosis infection had 
2.9 times great risk of virologic failure.
It is observed that the T CD4+ cell count baseline 
above 200 cells/mm3 was not statistically associated 
with virological failure, but the incidence of failure 
in this group was noticeably lower than in those with 
initial T CD4+ less than 200 cells/mm3. Studies con-
ducted by Skowron et al21 demonstrated that T CD4+ 
cell count is a better predictor of viral suppression. 
However,  in  order  to  achieve  viral  load  suppres-
sion to undetectable levels, it is necessary to have 
an optimal response of T CD4+ cell count in patients 
under   antiretroviral therapy. Piliero22 comments that 
the maximum suppression of viral replication remains 
the primary goal of therapy after HAART regimen, 
therefore T CD4+ cell count and HIV plasma viral 
load values are the prognostic markers for treatment 
success after four, eight or twelve weeks post treat-
ment, as the changes are predictive of favorable long-
term success in six months or more.
According to Moreno et al23 in multifailed patients, 
at least two active drugs can not be used, the thera-
peutic scheme should be kept in use until new drugs 
become available, assuming that there is an immuno-
logic and clinical stability in order to avoid the use of 
a drug from a common chemical group which usually 
leads to a rapid viral resistance development, further 
limiting future treatment options. Geretti et al24 stated 
that  patients  in  first  HAART  line  who  maintained 
consistently undetectable plasma viral load for a year, 
had a low risk of virologic failure.
In  this  study,  the  tuberculosis  comorbidity  had 
significant influence on the occurrence of virologic 
failure. Special attention should be given to early 
tuberculosis  diagnosis  during  the  early  HAART 
Table 5. Logistic regresion in patients attended in the health center no. 1 (hospital Dia) from 2002 to 2008.
step Variable β Wald test P-value Odds ratio Ic95%
Step 1 gender 1.142 1.718 0.182 3.132 0.586–16.746
Age 0.894 1.906 0.167 2.444 0.687–8.692
Skin colour 0.059 0.007 0.932 1.061 0.274–4.107
Marital status 0.512 0.588 0.443 1.668 0.451–6.170
education 0.745 1.129 0.288 2.106 0.533–8.319
Zone 0.149 0.034 0.854 1.160 0.237–5.683
Birthplace 1.240 3.656 0.056 3.454 0.969–12.310
expsosure category 0.580 0.475 0.491 1.786 0.343–9.301
Viral load after hAArT 21.291 0.000 1.000 0.000 0.000–0.000
T cD4+ after hAArT 0.451 0.417 0.518 1.569 0.400–6.156
hAArT -0.112 0.023 0.880 0.894 0.207–3.851
hBV (hBsAg) -0,539 0,210 0,647 0,583 0,058–5,859
hcV (anti hcV) -0.356 0.191 0.662 0.701 0.142–3.450
TB (B.A.A.r.) 1.107 2.536 0.111 3.025 0.775–11.810
constant -48.150 0.000 1.000 0.000 0.000–0.000
Step 14 Age 0.812 2.125 0.145 2.252 0.756–6.707
Birthplace 1.308 5.247 0.022 3.698 1.208–11.322
TB (B.A.A.r.) 1.311 4.786 0.029 3.710 1.146–12.008
constant -3.508 4.353 0.037 0.030 0.000–0.000
Paso 15 Birthplace 1.188 4.584 0.032 3.280 1.106–9.731
TB (B.A.A.r.) 1.340 5.098 0.024 3.820 1.194–12.229
constant -2.173 2.567 0.109 0.114 0.000–0.000
Abbreviations: β, maximum likehood values; hAArT, antiretroviral therapy; cD4+, lymphocyte count; IC95%, confidence interval; HCV, Hepatitis C Virus; 
anti HCV, antibody to the hepatitis “C” virus; HBV, Hepatitis B Virus; HBsAg, Hepatitis B Virus surface antigen; TB, tuberculosis; B.A.A.R, Alcohol acid 
resistant bacilli.Bello et al
40  Drug Target Insights 2011:5
  regimen    prescription.  Studies  reported  by  Bekker 
et al25 and von Reyn et al26 showed that the myco-
bacterial  disease  was  a  major  contributor  to  HIV 
mortality. In addition, the infection increases the risk 
of latent tuberculosis reactivation, a new infection 
progression or re-infection to active disease, increas-
ing the risk of the emergence of HIV resistant strains 
to  the  usual  antiretroviral  therapy.  Tuberculosis 
also accelerates the course of HIV induced disease 
by activating viral replication and accentuating the 
decline of T CD4+ cells.
In the logistic regresion analysis the best model 
to explain the event of virological failure is the one 
that includes variables such as origin and infection 
by M. tuberculosis, yielding OR values of 3.2 and 3.8 
respectively.
conclusion
Despite  the  enormous  progress  as  a  result  of  the 
impact  of  HAART-related  morbidity  and  mortality 
in patients with HIV/AIDS continue and will con-
tinue to fail in the face of the therapeutic classes of 
HAART  currently  available.  The  presented  results 
reinforce the importance of monitoring the biological 
markers T CD4+ cells and viral load in patients living 
with and without AIDS, both to ensure that viral rep-
lication is under control and to reassure the mainte-
nance of immune reconstitution compatible with life, 
and to predict the risk of developing resistance and 
therapeutic failures in the course of the treatment of 
HIV-infected people.
It should be noted that the sample size limited the 
analysis of this study, as the retrospective information 
taken from the medical records, excluded some data 
from the laboratory and the clinical follow up. The 
sample obtained in this way may have had a limited 
ability to highlight the predictive differences of risk 
for both T CD4+ cell count and viral load in naive 
patients.  It  is  possible  that  working  with  a  larger 
cohort of patients and longer follow-up of these pre-
dictors  probably  would  show  more  consistent  evi-
dence that is statistically supported. Initial treatment 
with any NNRTI-based regimen or an IP, but not both, 
is a good strategy for managing the long-term anti-
retroviral treatment in naive HIV patients. Moreover, 
the recent availability of new antiretroviral agents for 
the treatment of HIV has increased treatment options 
and improved durability, tolerability and efficacy in 
the long-term HAART regimen.
Other  limitations  that  should  be  highlighted 
refer to the possibility of verifying the association 
of HBV and HCV coinfections which do not have 
evolutionary studies of these HIV comorbidities. It 
is possible that if we had a homogeneous group of 
patients already in advanced stages of these patholo-
gies, the risk of virologic failure would be high. The 
sociodemographic  data  were  collected  from  medi-
cal records and not through interviews, this fact may 
also have skewed the results of the analysis of asso-
ciation between these variables and treatment failure. 
  However, this service data and variables accounted 
are limitations imposed by real situations in nosoco-
mial institutions in the Federal District in Brazil.
It is of great relevance to the findings in this study 
considering the limitations and difficulties of conduct-
ing studies in routine service, as it can be concluded 
that even in the non-ideal conditions of a clinical trial, 
patients treated in this unit had virological success of 
12.2% up to one year of treatment, a fact that can pre-
dict the durability of the first scheme which is better 
than expected in many other international centers.17 
Also tuberculosis infection should be traced as a pri-
ority as early as possible. As the low values of T CD4+ 
cell counts and high viral load pre-treatment should be 
considered to implement the prescribed antiretroviral 
therapy, especially when new classes are available and 
have superior performance, as much viral suppression 
and immune reconstitution could be achieved.
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